Sector Performance: The overall performance of the healthcare sector and, more specifically, the vaccine industry impacts investor sentiment and valuation of Valneva.

Clinical Trial Results: Positive or negative data from clinical trials for Valneva's vaccines significantly affects the stock price, driving investor confidence or concern.

Regulatory Approvals: Approval or rejection of Valneva's vaccines by regulatory bodies like the EMA and FDA has a direct and substantial impact on market access and revenue potential.

Competitive Landscape: Actions and developments from competitor vaccine manufacturers influence Valneva's market share and perceived value, thereby affecting its stock price.

Financial Performance: Valneva's revenue, profitability, and cash flow directly impact investor confidence and the attractiveness of the stock.

Macroeconomic Factors: Broader economic conditions, such as interest rates, inflation, and economic growth, can influence investor sentiment and overall market valuation of stocks.

Company-Specific News: Announcements about partnerships, acquisitions, or strategic changes within Valneva can lead to significant price movements.